Target intelligence / Profile preview

Protein kinase C C1 domain (C1 domain)

Target
C1 domain
Molecular classification
Protein domain, Lipid-binding domain, Regulatory domain
01

Overview

The Protein kinase C (PKC) C1 domain is a conserved, cysteine-rich regulatory module of approximately 50 amino acids that serves as the primary sensing site for the second messenger diacylglycerol (DAG) (Newton, A. C., 2018, Chemical Reviews). Found in conventional and novel PKC isoforms, this domain coordinates two zinc ions and possesses a hydrophobic groove that accommodates DAG or exogenous ligands such as phorbol esters and bryostatins (Igomenova, T. I., 2015, Biochemistry). Upon ligand binding, the C1 domain facilitates the translocation of the PKC enzyme from the cytosol to the plasma membrane, a critical step in the activation of various intracellular signaling pathways. This recruitment triggers a conformational change that releases the kinase's autoinhibitory pseudosubstrate, allowing for substrate phosphorylation and downstream signaling (Kourani et al., 2022, Frontiers in Drug Discovery). Because PKC signaling regulates vital processes such as cell growth, apoptosis, and synaptic plasticity, the C1 domain is a significant therapeutic target for conditions like cancer and Alzheimer's disease. Drugs targeting this domain, such as bryostatin-1 and ingenol mebutate, work by modulating PKC activity, though achieving isoform specificity remains a major challenge in drug development.

Other names
C1 regionCysteine-rich domainDAG-binding domainPhorbol ester binding site
02

Mechanism of action

Ligands bind to the C1 domain to mimic the natural activator diacylglycerol (DAG), inducing membrane translocation and allosteric activation of the kinase by releasing the pseudosubstrate.

03

Biological functions

Signal transductionLipid signalingProtein translocationEnzyme activationCellular differentiation
04

Disease associations

CancerAlzheimer's diseaseActinic keratosisHIV infectionDiabetic complications
05

Safety considerations

Tumor promotion riskOff-target activation of non-PKC C1 domains (e.g., RasGRP, Munc13)Systemic toxicity (e.g., myalgia)Risk of secondary malignancies (e.g., skin cancer)
06

Interacting drugs

Bryostatin-1

3 more in the full profile.

07

Biomarkers

Protein kinase C isoform expression levelsDiacylglycerol (DAG) levelsMARCKS phosphorylation statusProtein kinase C membrane translocation

Beyond the preview

Go deeper on Protein kinase C C1 domain (C1 domain).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein kinase C C1 domain (C1 domain).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call